Bltp3a-silenced antigen-specific engineered t cells
AssigneeRutgers, The State University of New Jersey
InventorsKyle Kristopher PAYNE, Fnu Rinkee KUMARI
Life of this patent
Estimating the term…
Abstract
Described herein are pharmaceutical compositions comprising antigen-specific engineered T cells comprising chimeric antigen receptor (CAR)-T cells, T cell receptor (TCR)-T cells, or tumor-infiltrating lymphocytes (TILs) having attenuated or terminated BLTP3A expression. In some embodiments, the antigen-specific engineered T cells have increased anti-cancer effector activity relative to antigen-specific engineered T cells having normal BLTP3A expression. Also described herein are methods of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of the pharmaceutical compositions described herein.
Claims28
A pharmaceutical composition comprising antigen-specific engineered T cells comprising chimeric antigen receptor (CAR)-T cells, T cell receptor (TCR)-T cells, or tumor-infiltrating lymphocytes (TILs) having attenuated or terminated BLTP3A expression.
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising antigen-specific engineered T cells comprising chimeric antigen receptor (CAR)-T cells, T cell receptor (TCR)-T cells, or tumor-infiltrating lymphocytes (TILs) having attenuated or terminated BLTP3A expression.
A method of producing antigen-specific engineered T cells comprising chimeric antigen receptor (CAR)-T cells, T cell receptor (TCR)-T cells, or tumor-infiltrating lymphocytes (TILs) having attenuated or terminated BLTP3A expression, the method comprising:
- treating the antigen-specific engineered T cells with a nucleic acid molecule specific to BLTP3A for a sufficient period of time to attenuate or terminate BLTP3A expression in the antigen-specific engineered T cells.
A method of increasing anti-cancer effector activity of antigen-specific engineered T cells comprising chimeric antigen receptor (CAR)-T cells, T cell receptor (TCR)-T cells, or tumor-infiltrating lymphocytes (TILs), the method comprising attenuating or terminating BLTP3A expression in the antigen-specific engineered T cells.
Dependencies are inferred from the claim text.